Avery Dennison has introduced a line of syringe labeling products to its pharmaceutical portfolio. The portfolio extension features safe, compliant label stock products that meet manufacturers’ high standards for syringe and tight mandrel pharmaceutical applications.
According to the IMS Institute for Healthcare Informatics, the global pharmaceutical segment is projected to grow to more than $1 trillion by 2018, with focused growth in the oncology, diabetes, and pain and autoimmune therapy areas. High-value drugs used to treat these ailments are commonly packaged in prefilled syringes or vials and require labels that will function according to the needs of the product as well as remain securely in place during storage and use.
The new Avery Dennison syringe portfolio includes labels that offer low migration and high-performance adhesives on flexible paper and film face stocks. Products are sterilization-friendly and resistant to heat, steam, and chemicals. Photoluminescent options are available to aid with missing label detection using ultraviolet light.
Adhesives used in the pharmaceutical industry must undergo comprehensive FDA testing to ensure they comply with toxicology requirements. If any adhesive changes are to occur, Avery Dennison notifies converters months in advance in order to make sure the new formulations are properly tested for compliance.
